Atrial Fibrillation
Conditions
Keywords
Non-valvular atrial fibrillation (NVAF), Prevention, Stroke
Brief summary
To obtain a better understanding on the comparative effectiveness of apixaban versus VKA (Vitamin K antagonist) for stroke prevention in patients with NVAF (Non-valvular atrial fibrillation) in a real-life setting.
Interventions
DRUGApixaban
As prescribed by treating physicians
As prescribed by treating physicians
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* NVAF will be defined as the occurrence of 2 or more inpatient or outpatient claims with ICD-9 427.31 as the diagnosis code at any time in the patient's data history prior to inclusion * Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics * CHA2DS2-Vasc (C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years; D: Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism; V: Vascular disease; A: Age 65-74 years; Sc: Sex category) score ≥2 during the 180 days prior to index apixaban use baseline period
Exclusion criteria
* Patients \<18 years of age * Patients with valvular AF (Atrial fibrillation) * Pregnancy * Malignant cancers * Transient cause of AF * Patients with VTE (Venous thromboembolism) (pulmonary embolism or DVT (Deep Vein Thrombosis)) * Patients with major surgery defined as hip or knee replacement * Prescriptions of OACs (Oral anticoagulants) (apixaban, warfarin, dabigatran, rivaroxaban) before index date * Prescription of more than one OAC on the index date * Patient with any of the events defined in the composite endpoint
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Hospitalization Events (composite endpoint) | Up to 2 years |
Countries
United States
Outcome results
None listed